692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC)
Carlo Cattrini, R. Lozano Mejorada, Vincenza Conteduca, María Dolores Martínez Ruíz, Martijn P. Lolkema, David Lorente, Shahneen Sandhu, Nuria Romero-Laorden, Yohann Loriot, Arun Azad, Luís Costa, Armelle Vinceneux, Ravindran Kanesvaran, Yüksel Ürün, Javier Puente, Gerhardt Attard, N. Mehra, Ugo De Giorgi, David Olmos, E. Castro Marcos (2020). 692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC). , 31, DOI: https://doi.org/10.1016/j.annonc.2020.08.2086.
